|
GSK PLC on Wednesday said it has completed the acquisition of Canada-based clinical stage biopharmaceutical firm 35Pharma Inc for $950 million in cash. The London-based pharmaceuticals company said 35Pharma specialises in the development of novel protein-based therapeutics. The acquisition includes HS235, a ‘potential best-in-class molecule for the treatment of pulmonary hypertension’, with proof-of concept trials expected to start imminently in two forms of the illness.. Pulmonary hypertension is a life-shortening disease marked by high blood pressure in the lungs. The transaction was first announced in February. ‘HS235 is an important addition to our [Respiratory, Immunology & Inflammation] pipeline, which continues to expand across inflammatory and fibrotic drivers underlying multiple chronic diseases,’ said Kaivan Khavandi, head of translation & development sciences at GSK. ‘With approximately 82 million patients currently living with [pulmonary hypertension] in its various forms, high burden of morbidity associated with the disease and poor associated prognosis, with low five-year survival rates, we are committed to advancing this novel, differentiated option to expand the limited treatments currently available.’ Shares in GSK were down 0.1% at 2,187.00 pence on Wednesday morning in London. Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
